President and CEO Robert Blum describes aficamten's mechanism, the trial's study design, and reflects on Cytokinetics' 25 years.

Steven Kelly describes how Carisma is leveraging Moderna's mRNA and LNP expertise to engineer monocytes in-vivo to act as a cell therapy.

Dan O'Connor and Shawn Zhang describe Ambrx's HER2 and PSMA targeting antibody-drug conjugate programs.

Troy Wilson describes the science behind Kura's menin inhibitor and farnesyl transferase inhibitor programs.

Jeff Keyser tells us about trying to help patients recover from surgeries more efficiently and the phase 2 data that led to Renibus' BTD.

Barbara Weber walks us through the science of PRMT5, shares her reaction to recent data, and describes how programs are designed differently

David Meeker describes Rhythm's focus on the melanocortin-4 receptor pathway and data presented this week for hypothalamic obesity.

Markus Warmuth describes the PK/PD variables the company is seeing, how safety is shaping up, and a partnership with Roche.

Josh Cohen and Justin Klee on the negative opinion, what it means for ALS patients in Europe, and a new statistical analysis of CENTAUR.

Mike Curtis explains how transplanted pig kidneys have shown durability (over two years) in some non-human primates.

Sebastian Guth discusses areas of focus like oncology, cardiovascular disease, and women's health.

CEO Laurent Levy walks us through the data and makes his argument that patients' OS was greater than what would be expected.

Victor Velculescu and Peter Bach explain how their new lung cancer test is design to help more people get screened for lung cancer.

Steve Hahn describes how Harbinger Health is trying to catch the earliest signals of cancer, and how this information might be used.

Niko Kley explains the concept of molecular glues, and how Orionis is also trying to design cytokines that are selectively activated.

Rosana Kapeller explains how Rome is looking at areas of the genome that do not encode for traditional proteins as the basis of disease.

Mike Nally describes Generate's near term programs how he sees computational advances changing where the field is headed over the long term.

Stephen Hoge explains how Moderna is partnering on programs that include CAR-T, TCRs, bi-specifics, and in-vivo editing programs.

Stéphane Bancel comments on the fall covid vaccine rollout, pushing into earlier stages of cancer, and rare diseases.

Simon Read discusses the use cases for radiopharmaceuticals and why Mariana has chosen small cell lung cancer for its first indication.